- Announces topline results from REVEAL2, the second Phase 3 trial evaluating VGX-3100 as a treatment for cervical high-grade squamous intraepithelial lesions (HSIL)
- Trial results did not meet the primary endpoint in the biomarker-selected population
- Trial results did achieve statistical significance in the all-participants population
- Trial results did not meet the primary endpoint in the biomarker-selected population
TripAdvisor Stock Is Trading Higher Tuesday: What’s Going On?
TripAdvisor Inc (NASDAQ: TRIP) shares are moving higher Tuesday after the company reported better-than-expected financial results. Here's a
